The global sentinel lymph node biopsy imaging agents market size was estimated at USD 101.48 million in 2025 and is projected to reach USD 184.10 million by 2033, growing at a CAGR of 7.96% from 2026 to 2033. The market is primarily driven by the rising global burden of cancer, particularly breast cancer and melanoma, which is increasing the need for accurate staging and precise lymphatic mapping techniques. Sentinel lymph node biopsy (SLNB) has become an essential procedure in oncology because it enables physicians to determine whether cancer has spread to nearby lymph nodes while minimizing the need for more extensive surgical interventions. As healthcare systems increasingly shift toward minimally invasive diagnostic and surgical procedures, SLNB is being preferred over full lymph node dissection due to its ability to reduce complications such as lymphedema, lower postoperative pain, shorten hospital stays, and support faster patient recovery. These clinical advantages are significantly boosting demand for advanced imaging agents used during SLNB procedures.
Moreover, ongoing technological advancements in radiotracers, fluorescent dyes, and hybrid imaging agents are significantly improving detection accuracy, surgical precision, and overall patient outcomes, thereby encouraging wider adoption of these products in oncology practice. Innovations such as near-infrared fluorescence imaging, dual-modality tracers, and enhanced radiopharmaceutical formulations are enabling surgeons to identify sentinel lymph nodes more effectively and with greater confidence. In addition, growing clinical research activities, increasing regulatory approvals, and rising public and private funding in oncology are supporting the development and commercialization of next-generation imaging agents. Greater awareness regarding the importance of early cancer detection and precise staging is also contributing to the broader use of sentinel lymph node biopsy techniques worldwide. Together, these factors are accelerating the expansion of the sentinel lymph node biopsy imaging agents market and creating significant opportunities for continued technological advancement and clinical adoption.
Key Market Trends & Insights
• North America dominated the global sentinel lymph node biopsy imaging agents industry and accounted for the largest revenue share of 42.50% in 2025. The region’s leadership is supported by a high prevalence of cancer, particularly breast cancer and melanoma, well-established healthcare infrastructure, and widespread adoption of advanced diagnostic and surgical technologies. Healthcare providers across North America increasingly utilize sentinel lymph node biopsy procedures to enable accurate cancer staging while minimizing surgical complications and improving patient outcomes. In addition, strong investments in oncology research, favorable reimbursement systems, and the presence of leading pharmaceutical and medical imaging companies continue to reinforce the region’s dominant position in the market.
• By product, the radioactive tracers segment led the market with the largest revenue share in 2025. Radioactive tracers remain the most widely used products for sentinel lymph node mapping because they provide highly reliable localization of sentinel nodes and have long been established as a standard of care in oncology procedures. These tracers are commonly used in conjunction with gamma detection systems to guide surgeons during cancer staging surgeries. Their proven clinical effectiveness, extensive physician familiarity, and broad regulatory acceptance have contributed significantly to their leading market position.
• By application, the breast cancer segment led the market with the largest revenue share in 2025. Breast cancer represents one of the most common indications for sentinel lymph node biopsy, as accurate assessment of lymph node involvement is essential for determining disease stage and selecting appropriate treatment strategies. The high incidence of breast cancer worldwide, coupled with established clinical guidelines recommending SLNB as a standard diagnostic procedure, continues to drive substantial demand for imaging agents within this application segment.
• By procedure, the open surgery segment led the market with the largest revenue share in 2025. Open surgical procedures continue to account for a significant share of sentinel lymph node biopsy applications, particularly in healthcare settings where traditional surgical approaches remain widely practiced. These procedures allow direct visualization and access to the lymphatic system, enabling precise use of imaging agents to identify and remove sentinel lymph nodes. Their continued adoption in many hospitals and oncology centers supports the segment’s leading market share.
• By end use, the hospitals segment led the market with the largest revenue share in 2025. Hospitals are the primary settings for cancer diagnosis and surgical treatment, offering the specialized facilities, nuclear medicine capabilities, and multidisciplinary oncology teams required to perform sentinel lymph node biopsy procedures. The high volume of cancer surgeries conducted in hospitals, along with access to advanced imaging technologies and comprehensive patient care services, has enabled this segment to maintain the largest share of the sentinel lymph node biopsy imaging agents market.
Looking for more specific insights? Customize this report to suite your business needs
Key Sentinel Lymph Node Biopsy Imaging Agents Companies
The following key companies have been profiled for this study on the sentinel lymph node biopsy imaging agents market. These companies represent some of the most prominent participants in the industry and play a critical role in the development, manufacturing, and commercialization of imaging agents used in sentinel lymph node biopsy (SLNB) procedures. Their product portfolios include radioactive tracers, fluorescent dyes, and hybrid imaging agents designed to improve the accuracy of lymphatic mapping and support precise cancer staging, particularly in breast cancer, melanoma, and other solid tumors.
These organizations are actively engaged in research and development to introduce innovative products that enhance detection sensitivity, reduce procedural complexity, and improve surgical outcomes. Many of them are also pursuing strategic initiatives such as regulatory approvals, clinical collaborations, licensing agreements, and geographic expansion to strengthen their market presence. With growing demand for minimally invasive oncology diagnostics and increasing emphasis on early cancer detection, these companies continue to contribute significantly to the advancement and commercialization of next-generation sentinel lymph node biopsy imaging agents worldwide.
The following key companies have been profiled for this study on the sentinel lymph node biopsy imaging agents market.
• Cardinal Health
• Curium Pharma
• Jubilant Pharmova
• Guerbet
• Diagnostic Green
• Sun Pharmaceutical Industries, Inc.
• GE HealthCare
• VIATRIS (Mylan Inc.)
• Macsen Labs
• POLATOM
• Hologic Inc.
Grand View Research offers
√ Focused market intelligence reports on specific geographies or high-growth segments.
√ Extended forecast timelines for long-term planning.
√ Competitor Benchmarking and Supply Chain Analysis
√ Inclusion of regulatory and policy assessments.
√ Inclusion of custom data models, KPIs, or applications unique to your business
√ Specific high-impact Data Decks and Tables to support effective decision making
And much more…
Looking for a report customized to your requirements? Explore our Custom Research Offering
English
French
Spanish
Portuguese
Deutsch
Turkish
Dutch
Italiano
Russian
Romaian
Portuguese (Brazil)
Tiếng Việt